AFC
PTGX icon

Ares Financial Consulting’s Protagonist Therapeutics PTGX Stock Holding History

Ares Financial Consulting’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$735 Buy
+6
New +$627 ﹤0.01% 1045

Other funds holding PTGX

JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Ares Financial Consulting's PTGX Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 6 shares worth $735. The stake represents ﹤0.01% of the portfolio and ranks #1045 among its holdings.

110 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Ares Financial Consulting held 6 shares of Protagonist Therapeutics worth $735 as of Q2 2026.
  • Protagonist Therapeutics was a new Ares Financial Consulting position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1045 holding.
  • 110 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.